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Abstract
Context—HIV-related fatigue remains the most frequent complaint of seropositive patients.
Objectives—To describe the natural course of fatigue in HIV infection, in a sample (n=128) 
followed for a three-year period.
Methods—A longitudinal prospective design was used to determine what factors influenced 
changes in fatigue intensity and fatigue-related impairment of functioning in a community-
dwelling sample of HIV-infected individuals. Participants were followed every six months for a 
three-year period. At each study visit, we collected data on a large number of physiological and 
psychosocial markers that have been shown to be related to fatigue in HIV-infected people. At 
three-month intervals between study visits, we collected data on fatigue via mailed questionnaires.
Results—Fatigue in HIV infection is largely a result of stressful life events, and is closely tied to 
the anxiety and depression that accompany such events. Fatigue did not remit spontaneously over 
the course of the study, indicating the need for interventions to ameliorate this debilitating 
symptom.
Conclusion—Intervening to help people who are suffering from HIV-related fatigue to deal with 
stressful life events may help to ameliorate this debilitating symptom.
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“Fatigue does not kill but it is common, disabling, and is regarded as a serious symptom by 
our patients, who may be victims of a variant of Tudor Hart's inverse care law – an inverse 
interest law - that the commoner a condition, the less the professional interest.”1
Fatigue continues to be a troubling symptom for many with HIV infection,2 with an 
estimated prevalence of 33-88%.3 Research conducted in this area has been problematic: we 
have detailed in other papers a lack of consistent measurement; a lack of research focus on 
fatigue as a primary outcome of interest; a lack of longitudinal studies; and a failure to 
include multiple potential predictors of fatigue in data collection.4-6 We have published 
several reports of our findings,5,7-13 and there have been a number of other studies 
examining physiological and/or psychosocial factors related to fatigue in HIV infection; 
these are described below.
Since Jong et al. completed a comprehensive review of the literature in this area in 2010,3 
this review is focused on research conducted since that time. In their review, they found that 
the strongest predictors of fatigue among sociodemographic variables were unemployment 
and inadequate income. With regard to HIV-associated factors, combined antiretroviral 
therapy (ART) was the strongest predictor of fatigue. Interestingly, laboratory values were 
not predictive of fatigue. The strongest predictors were psychological factors such as 
depression and anxiety. They found that therapeutic interventions included testosterone, 
psychostimulants, dehydroepiandosterone (DHEA), fluoxetine, and cognitive behavioral or 
relaxation therapy.3 These authors recommended the use of the HIV-Related Fatigue Scale, 
developed by the first author and used in the study reported herein.
Research published since the Jong et al. review3 has extended our understanding of HIV-
related fatigue. With regard to ART and illness-related variables, a recent meta-analysis 
found that fatigue still interferes with antiretroviral adherence;14 however, fatigue was also 
among several factors that predicted virologic failure independent of adherence measures.15 
Fatigue was reported as the most frequent side effect of antiretroviral medications (71% of 
953 participants), and was associated with worse health status, decreased work productivity, 
and/or increased health care resource use.16
Sleep disturbances in HIV-infected patients are understood now in greater detail, especially 
their relationship to psychological states. Lack of energy, which is closely related to fatigue, 
is associated with sleep disturbance, anxiety and depressive symptoms; lack of energy is 
more strongly related to morning fatigue than to evening fatigue.17 Chinese women with 
HIV infection reported stress that was causing sleeplessness and fatigue.18 Actigraphy 
revealed that the women did not have refreshing nocturnal sleep; they reported nightmares, 
worrying about disclosure of their diagnosis and transmission of the virus.18 Insomnia 
severity scores were correlated with fatigue and anxiety symptoms in another study; sleep 
latency on two-week actigraphy was longer for HIV-infected participants, and sleep quality 
was reduced.19 Trouble sleeping is associated with poor antiretroviral adherence.20 HIV-
infected participants who report difficulty falling asleep experience greater sleep disturbance 
and symptom burden, particularly anxiety and morning fatigue.21 Greater insomnia severity 
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is associated with greater fatigue severity, and depression may contribute to both fatigue and 
insomnia.22 High fatigue in both morning and evening is associated with anxiety, 
depression, and sleep disturbance.23 Stress causes people living with HIV to become 
sleepless and fatigued; there were significant levels of sleep disturbance and fatigue, which 
were a result of the perceived stress of living with HIV infection.24
Of the psychosocial variables that have been correlated with fatigue, depression has been 
strongly and consistently related to fatigue in a number of studies. Anxiety, traumatic life 
events, post-traumatic stress disorder (PTSD), a lack of social support, and stressful life 
events also have been related to fatigue. Spirituality and religiosity predict increased 
religious coping, which influences social support, which in turn positively influences 
depression, which affects fatigue, and both depression and fatigue predict self-reported 
physical function.25 Psychological factors such as depression, anger and fatigue contribute 
to the level of distress experienced with HIV-related symptoms.26 Depression has long been 
associated with fatigue across illnesses, including HIV infection.27 In the review by Jong 
and colleagues,3 the strongest and most uniform associations were observed between fatigue 
and psychosocial factors such as depression and anxiety.
There is less evidence that physiological factors are associated with HIV-related fatigue, but 
there are some intriguing findings. The biological mechanisms are not well characterized. In 
an investigation of low-abundance plasma proteins in patients treated with nucleoside 
reverse transcriptase inhibitors (NRTIs) or those who were treatment naïve, the peptides 
apolipoprotein A-1, apolipoprotein B, histine-rich glycoprotein, alpha-1 B glycoprotein, and 
orosomucoid 2 were correlated with severity of fatigue; ApoA1 levels were higher in 
untreated patients, while ApoB results suggested a positive trend in treated patients.28 A 
high fatigue pattern was associated with five single nucleotide polymorphisms in a study of 
plasma cytokines; this strengthens evidence for an association between fatigue and 
inflammation.29 Fatigue was very common, despite viral suppression and good immune 
function; in a subgroup of patients, prior d-drug exposure and the presence of clinical 
lipodystrophy syndrome were associated with fatigue.30 Fatigue severity was correlated 
strongly with symptomatic orthostatic intolerance. The literature on the relationship of 
fatigue to CD4 count and HIV viral load remains inconclusive; less fatigue was related to 
higher CD4 counts and lower HIV viral loads in a recent study.31 Fatigued participants had 
lower levels of the cellular energy marker total creatine in the basal ganglia; this indicates 
energy dysmetabolism in this brain region, with striatal-cortical circuitry involvement.27 
Voss et al.32 found fatigue-related gene networks in CD(14)+ cells; they identified 32 genes 
that were predictive of low versus high fatigue, along with mitochondrial inner membrane 
proteins. Neuropathic-related numbness preceded reports of fatigue, and muscle aches and 
numbness explained 28% of the random variance in the occurrence of fatigue.33
There have been few intervention studies. In a review of treatment strategies, Jong et al.3 
noted that studies on treatment strategies were minor in nature and focused on a select group 
of patients, most of whom had a major depressive disorder or clinical hypogonadism. 
Modafinil and armodafinil are the treatments with the most evidence; there have been 
multiple studies with robust sample sizes conducted by Rabkin and colleagues34-39 and the 
results have consistently been reported as being effective in treating HIV-related fatigue.
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Our work on nighttime sleep quality, daytime sleepiness, stressful life events, and HIV-
related fatigue in this sample has been reported elsewhere.10 We report here data on the 
following aim: to examine prospectively the relationships of personal and HIV-related 
variables and changes in physiological and psychosocial variables to fatigue intensity and 
fatigue-related impairment of functioning over time in HIV-infected individuals.
Methods
Sample
HIV-infected individuals 21 years of age or older who could read and speak English and 
were mentally competent to provide reliable data were considered eligible for the study. 
Mental competence and conditions that would preclude successful completion of the study 
were assessed during a detailed telephone screening interview by the principal investigator 
(PI). A total of 128 fatigued and non-fatigued persons were enrolled. Persons with a 
comorbid condition marked by fatigue were excluded, as were pregnant women and women 
less than 12 months postpartum. Flyers advertising the study were distributed at HIV/AIDS 
treatment centers and service organizations in North Carolina; these treatment centers are 
regional referral centers for patients from surrounding states. Although the word fatigue was 
prominent on the flyer, it stated that the study was open to both fatigued and non-fatigued 
people. The Institutional Review Board at Duke University Medical Center approved the 
study protocol, and study data were protected with a Certificate of Confidentiality from the 
National Institutes of Health. Written informed consent was obtained from each participant.
Procedures
Persons interested in participating in the study contacted the PI, who conducted the 
preliminary screenings by telephone. Participants were enrolled over a 14-month period. 
Potential participants were then contacted by one of the two study coordinators, and an 
initial visit was scheduled. The study visits were conducted at Duke’s Clinical Research 
Unit. Participants were encouraged to take breaks whenever they became tired. They were 
paid $70 for each study visit. Study participants came in for a baseline visit and then every 
six months for three years, for a total of seven study visits. At each study visit, we collected 
data on a large number of physiological and psychosocial markers that have been shown to 
be related to fatigue in HIV-infected people. At three-month intervals between study visits, 
we collected data on fatigue via mailed questionnaires. All measures were performed at each 
visit, except when noted below, and all data were collected in face-to-face interviews and 
self-report questionnaires. The interviews and questionnaires were completed first, then 
blood was drawn for the physiological measures. Baseline demographic/medical data were 
collected at the first study visit by one of two research assistants. Patients were asked to rate 
their current health status at each study visit, and no participant reported receiving treatment 
for HIV-related fatigue during the study. We retained 78% of the participants for all seven 
data collection points. We allowed people to resume study visits if they missed a visit. There 
were no significant differences in fatigue scores among those who left the study and those 
who remained.
Barroso et al. Page 4














Physiological measures included hepatic function (AST, ALT, GGT, alk phos, T. bili, 
hepatitis C status), thyroid function (TSH, T4), HIV viral load, immunologic function (CD4, 
CD8, CD4/CD8 ratio, CD16, CD8CD38), gonadal function (testosterone, DHEA), 
hematologic function (hemoglobin, hematocrit, serum erythropoietin), and cellular injury 
(lactic acid). Thyroid and gonadal function were measured yearly because they are not 
subject to rapid change. Samples were transported and processed in the appropriate labs at 
Duke University Medical Center, using standard assay procedures. These labs are accredited 
by the College of American Pathologists and the Health Care Finance Administration.
Fatigue and Psychosocial Measures
Fatigue—The HIV-Related Fatigue Scale (HRFS)4,5 is a Likert-type self-report measure 
with two scales measuring fatigue intensity (eight items, reported Cronbach’s alpha 0.93) 
and impact of fatigue on daily functioning (22 items, reported Cronbach’s alpha 0.98). A 
higher score on scales and items indicates more intense fatigue or greater adverse impact of 
fatigue; a mean score of ≥7 on the intensity scale indicates severe fatigue. Subjects whose 
intensity of fatigue is low (1 or 2) on all of the first seven HRFS items (i.e., my level of 
fatigue today; my level of fatigue on most days; how severe is the fatigue) are told to skip 
the rest of the instrument, because all of the remaining items are dependent on the subject 
being fatigued. Therefore, the few subjects with virtually no fatigue (n = 17) were given a 
“1” on all scales, subscales, and individual items.
Traumatic Events—Number of categories of traumatic events was adapted from previous 
research40-43 and was assessed with a detailed interview. Childhood trauma was constructed 
by assigning one point for each of 14 traumas occurring at or before age 18. The number of 
categories of adult trauma included seven types of trauma occurring after age 18. Number of 
categories or types of traumatic events has been widely used in research; experiencing more 
types of trauma has been shown to predict higher rates of life-threatening medical conditions 
among health maintenance organization patients40 and higher risk for mortality in HIV.44 
Because of our interest in predictors of fatigue, in this study we examined the number of 
categories of childhood and adult trauma separately.
Stressful Life Events—Recent stressful life events were measured via a methodology 
developed in a previous nine-year study showing that cumulative stressors predicted faster 
HIV disease progression.45-47 Subjects completed a checklist of possible stressful life events 
and difficulties experienced during the previous six months (list originally modified from 
the Psychiatric Epidemiology Research Interview).48 Subjects were then interviewed 
concerning the nature and context of each of the endorsed stresses. Interviewers objectively 
rated each stress from zero (no threat) to four (severe threat) using a manual of norms and 
vignettes, a methodology similar to that developed by Brown and Harris.49 Norms for each 
stressful event were based on the degree of threat that most people would experience given 
the particular circumstances (e.g., financial impact, life threat, personal involvement). The 
objective threat rating was made independently from the subject’s appraisal, in order to 
reduce the possibility that worsening disease or fatigue might lead to higher stressful event 
scores. The two research assistants were trained by one of the investigators (J.L.). They were 
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allowed to rate stresses independently, once they achieved reliability with the investigator’s 
ratings (89–90% agreement, kappa = 0.83). Periodic reliability checks and retraining were 
done to insure that the interviewers maintained their consistency. All stresses rated above 
one were summed, except that we removed stressors that were likely to be caused by disease 
progression (e.g., CD4 count decline, retirement because of HIV worsening). We did not 
count stresses rated one, as these were typically positive stresses (e.g., job promotion) or 
daily hassles.
Depressive Symptoms—Depressive symptoms were measured with the Beck 
Depression Inventory-II (BDI-II), a 21-item instrument that assesses cognitive, affective and 
somatic symptoms of depression.50 This widely used inventory has acceptable test-retest 
reliability (r = 0.79) in a nonclinical population. A score above 14 on the BDI-II is indicative 
of depression, with scores of 20–28 indicating moderate depression, and scores of 29 or 
above indicating severe depression. We omitted somatic symptom items that might overlap 
with HIV-related medical symptoms, thus changing the cut-off score for depression to 10.
Anxiety—The Hospital Anxiety and Depression Scale (HADS)51 was used to measure 
anxiety. The HADS is a self-assessment mood scale, without somatic items, designed to 
identify non-organic anxiety and depressive states. Because the BDI-II and the HADS 
depression scales were highly correlated, we report only the anxiety findings from this scale. 
A score of 10 or higher on the anxiety subscale is diagnostic for that condition.51 The 
anxiety subscale has a reported Cronbach’s alpha of 0.89, showing strong internal 
consistency, and it correlates highly with the State Trait Anxiety Inventory (r = 0.68).52
Social Support—The Medical Outcomes Study Social Support Survey (MOS-SSS) 
contains 20 items that assess overall social support as well as five dimensions of support: 
emotional, informational, tangible, positive social interaction, and affectionate.53 The scale 
uses a 1–5 Likert type rating scale (range, 20–100), with higher scores indicating greater 
support. Reported Cronbach’s alphas are high for all of the subscales and for the total score 
(range, 0.91–0.97); one-year stability coefficients for the scales were also high (range, 0.72–
0.79). In published reports, the instrument correlated strongly with other social support 
measures and was associated with a variety of mental and physical health outcome variables. 
Social support is measured yearly because it is a relatively stable variable.53
Post-Traumatic Stress Disorder (PTSD)—The Davidson Trauma Scale54 was used to 
measure PTSD. It is a 17-item self-report measure, using a 5-point Likert rating scale, and it 
is based on the PTSD symptom clusters defined by the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM-IV). Scores range from 0 to 68 for each of the 
frequency and severity scales, and a score of 40 is diagnostic of PTSD. The total scale has 
demonstrated good test-retest reliability (r = 0.86) and internal consistency (r = 0.99). In 
diagnosing PTSD compared to the Structured Clinical Interview for DSM-IV Diagnoses 
(SCID), the positive predictive value was 92% and the negative predictive value was 79%.
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We used linear mixed-effects regression models to calculate unadjusted and adjusted effects 
of each physiologic and psychosocial measure on fatigue intensity and fatigue-related 
impairment of functioning. Each model allowed for an effect of time and included person-
specific random intercepts. In these models, the level of each physiologic and psychosocial 
measure was broken down into two terms.55 The first term, representing a between-person 
effect, contained each individual’s mean value on a given variable averaged across all 
measured time points. In the mixed models, coefficients for these between-person terms 
reflect the association between an individual’s average level of a given measure and that 
individual’s average level of fatigue. The second term, representing a within-person effect, 
contained the person’s deviation at each point in time from his or her overall mean on a 
given variable. In the mixed models, coefficients for these within-person terms reflect the 
association, for any individual, between changes in a given measure over time and 
contemporaneous change in fatigue. All physiologic and psychosocial variables were 
rescaled to have a standard deviation (SD) of 1.0 before modeling, such that reported 
coefficients represent the expected change in fatigue level, on a 1-10 scale, for a one SD 
change in the independent variable.
The ordering of predictor variables was determined empirically. We fit a series of nested 
models corresponding to our conceptual model of the relationships between 
sociodemographic, clinical, and psychosocial variables, and fatigue. Model 1a included 
sociodemographic variables that demonstrated statistically significant associations (at 
P<0.05) with either fatigue intensity or fatigue-related impairment of functioning, as well as 
three clinical indicators of a priori interest: CD4 count, HIV RNA viral load, and whether 
the participant was on ART. Model 1b included all variables from Model 1a as well as two 
additional laboratory values that demonstrated marginally significant bivariable associations 
with fatigue intensity: total testosterone and DHEA. Model 1c included all variables from 
Model 1b as well as lifetime exposure to traumatic experiences.
In Model 2, we introduced between- and within-person measures of exposure to recent 
stressful events and social support to test the hypothesis that these constructs would mediate 
any observed association between trauma and fatigue.56-58
In Models 3a-3c, we tested the hypothesis that current mental health symptomatology would 
mediate any association between recent stressful life events and fatigue.59-61 In each model 
we introduced one of three measures of current mental health status: PTSD symptoms 
(Model 3a), anxiety symptoms (Model 3b), or depression symptoms (Model 3c). These 
measures were not included in a single model because of collinearity.
Results
Table 1 includes demographic data about the sample. We admitted fatigued (n=111) and 
non-fatigued (n=17) HIV-infected participants into the study. The majority of subjects were 
African American (66%), men (66%), unemployed (67%), and on ART (82%). The 
demographic distribution of the sample closely mirrors the HIV epidemiologic data for the 
state of North Carolina and the broader Southeast.62 The median age was 44 years. The 
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median number of years of education was 12, and the median monthly income of the sample 
was $685. The sample predominantly comprised people who had lived with HIV infection 
for a long time, with a median of 10 years since diagnosis (range, 0-25 years). The mean 
CD4 count was 517/mm3 (median 457), and 68% of the sample had HIV RNA viral loads 
<400 copies/mL.
Table 2 shows the unadjusted effects of sociodemographic and clinical characteristics with 
fatigue intensity and functioning over three years. Fatigue intensity and impairment of 
functioning tended to be higher among African Americans, among those with fewer years of 
education, and among those with lower incomes.
Tables 3 and 4 present unadjusted between- and within-person associations of psychosocial 
and physiological variables with the fatigue measures. Again, estimates for the between-
person association reflect the effect of an individual participant’s average over time, and the 
estimates for the within-person association reflect the effect of an individual participant’s 
change over time. Childhood trauma was measured at the baseline visit only because it 
represents events that occurred in the distant past and does not change over time. For most 
psychosocial measures, both the between-person (mean) and within-person (deviation) 
effects were strong and significant increases in psychosocial distress were associated with 
increases in fatigue. On average, a one SD difference in mean depression score was 
associated with a 1.52 points higher score on the fatigue-related impairment of functioning 
scale (between-person effect; P < 0.001). Additionally, a within-person one SD change in 
their depression score was associated with a 0.66 point SD increase in fatigue-related 
impairment of functioning (within-person effect; P < 0.001). The largest effect sizes were 
observed for depression and anxiety, with a somewhat smaller effect size for PTSD and 
stressful life events. Effect sizes were generally comparable when modeling fatigue intensity 
(Table 3) compared to fatigue-related impairment of functioning (Table 4). Few 
physiological variables were related to fatigue intensity or fatigue-related impairment of 
functioning. Exceptions were between-person associations between testosterone, DHEA, 
and fatigue intensity; a between-person association between testosterone and fatigue-related 
impairment of functioning; and a within-person association between serum erythropoietin 
and fatigue-related impairment of functioning.
Table 5 presents the adjusted effects of clinical and psychosocial variables on fatigue 
intensity. After controlling for other factors, the between-person term for income was the 
only sociodemographic or clinical variable that remained significantly associated with 
fatigue (Model 1b). Each additional lifetime traumatic experience was associated with a 
0.068-point higher fatigue score (Model 1c). Consistent with our mediation hypothesis, 
lifetime trauma had a nearly null association with fatigue intensity after including recent 
stressful events and social support in the model (Model 2).
In Model 2, each additional SD increase in recent stressful events was associated with a 0.43 
point higher fatigue intensity score (between-person association). This association was 
partially attenuated but remained elevated and significant after adjustment for measures of 
current mental health (Models 3a-3c), consistent with a hypothesis that current mental health 
partially mediates the effect of stress on fatigue but that stress retains a direct effect on 
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fatigue independent of current mental health symptoms. The measures of mental health 
symptomatology were themselves strongly associated with fatigue intensity, with a one-SD 
increase in PTSD, anxiety, and depression symptoms corresponding to a 0.33, 0.53, and 0.48 
point increase in fatigue intensity, respectively (between-person associations). The within-
person associations were similar in direction and statistical significance to the between-
person associations but smaller in magnitude.
Discussion
This study was designed to provide a prospective, longitudinal description of the natural 
course of fatigue in HIV-infected persons. Our sample of 128 people was typical of those 
with HIV infection in the southeastern U.S.: the majority of subjects were middle-aged, 
male, poor, unemployed African Americans. That most were African American somewhat 
limits the generalizability of our findings, but that is who is infected in the Deep South. We 
were interested in determining the chronicity of fatigue, and whether or not it would remit 
spontaneously over the course of the study. The participants who were the most fatigued at 
study entry were still the most fatigued at the end of data collection three years later. Also of 
note is that fatigue does not appear to remit spontaneously, which lends to the urgency to 
develop interventions for those who are most fatigued.
Over the three years of data collection, fatigue intensity and impairment of functioning 
tended to be higher among African Americans, among those with fewer years of education, 
and among those with lower incomes. People with fewer years of education tend to be in 
blue collar jobs that pay lower wages, and these jobs are often much more physically 
demanding than the white collar jobs available to those with more education. People with 
higher incomes often are able to hire people to do the most demanding activities, e.g., yard 
work, cleaning the house. We do not think that lower income affected access to care in our 
sample, as all reported having a primary care provider, and there was adequate clinical care 
for people with HIV infection, including those with limited funds or health insurance, in this 
particular geographical area.
Few physiological variables were related to fatigue intensity or fatigue-related impairment 
of functioning. After controlling for other factors, income was the only sociodemographic or 
clinical variable that remained significantly associated with fatigue. Each additional standard 
deviation increase in recent stressful events was associated with a 0.43 point higher fatigue 
intensity score. This association was partially attenuated but remained elevated and 
significant after adjustment for measures of current mental health (PTSD, anxiety and 
depression), consistent with our hypothesis that current mental health partially mediates the 
effect of stress on fatigue but that stress retains a direct effect on fatigue independent of 
current mental health symptoms. The measures of mental health symptomatology were 
themselves strongly associated with fatigue intensity, with a one SD increase in PTSD, 
anxiety, and depression symptoms corresponding to a 0.33, 0.53, and 0.48 point increase in 
fatigue intensity, respectively. Given the strong relationship between psychosocial factors 
and fatigue, Jong and colleagues3 recommended research comparing the effects of 
medication (antidepressants, anxiolytics) and behavioral interventions (cognitive behavioral 
therapy, relaxation therapy, graded exercise therapy) to direct the best treatment strategy.
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Several of our findings are striking; the longer a subject had been HIV-infected, the less 
fatigue they reported. It is possible that they have learned adaptive coping strategies that 
have helped them live with HIV as a chronic, manageable illness; it is also possible that they 
have modified their lives in incremental steps to accommodate fatigue. It is useful to know 
that physiological variables, including those that are disease markers for HIV infection, are 
not predictors of fatigue. Our findings suggest that monitoring lab values has little utility in 
identifying a cause for fatigue. It would still be appropriate to check for anemia and/or 
hypogonadism, but beyond that, there is no evidence that points to a physiological factor as 
a predictor of fatigue. Because of its unrelenting nature, it is critical that interventions be 
developed to lessen fatigue and its debilitating effects on HIV-infected individuals.
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Table 1
Description of sample
Characteristic N (%) or Median
(IQR)*
Demographic
Age, years (range: 26-66) 44 (38-48)
Male gender 84 (65.6%)
Race:
 African American 84 (65.6%)
 Caucasian 39 (30.5%)
 Other 5 (3.9%)
Years of schooling (range: 4-20) 12 (12-14)
Employed part/full time 42 (32.8%)
Monthly income, $ (range: 0-6000) 685 (501-1300)
Clinical
Years since HIV diagnosis (range: 0-25) 10 (6-15)
On any antiretroviral therapy 105 (82.0%)
CD4 count, cells/mm3 (range: 29-1755) 457 (268-670)
HIV RNA viral load <400 copies/mL 87 (68.0%)
Fatigue course
Fatigued at baseline 111 (88.1%)
Experienced remission of fatigue during follow-up** 11 (10.7%)
BLD: Below the limit of detection (400 copies/mL)
*
IQR interquartile range (25th–75th percentile)
**
Of 103 participants fatigued at baseline and with at least one follow-up visit.
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Table 2
Bivariable predictors of fatigue intensity and impact on functioning over 3 years
Intensity Impact on functioning
Predictor Coefficient 95% CI Coefficient 95% CI
Time since baseline, per 6 months −0.01 (−0.02, 0.00) −0.01 (−0.02, 0.00)
Mail-in (vs. in-person) assessment 0.44 (0.31, 0.56) 0.43 (0.30, 0.57)
Baseline fatigue intensity
  Baseline characteristics
Male gender −0.56 (−1.29, 0.16) −0.41 (−1.16, 0.34)
African American race 0.70 (−0.01, 1.42) 0.91 (0.18, 1.65)
Education, per year −0.20 (−0.33, −0.07) −0.22 (−0.35, −0.08)
 Time-varying sociodemographic
characteristics
Age, per 10 years 0.14 (−0.35, 0.63) 0.23 (−0.27, 0.74)
Income, per log10 −0.30 (−0.48, −0.13) −0.25 (−0.43, −0.08)
Employed −0.06 (−0.34, 0.21) 0.19 (−0.09, 0.47)
  Time-varying clinical characteristics
Years since HIV diagnosis, per year −0.06 (−0.12, −0.01) −0.07 (−0.13, −0.01)
On antiretroviral therapy 0.04 (−0.20, 0.29) 0.05 (−0.20, 0.31)
CD4, per 100 cells/mm3 −0.05 (−0.12, 0.01) −0.03 (−0.09, 0.04)
HIV RNA viral load, per log10 0.12 (−0.02, 0.25) 0.04 (−0.09, 0.18)
On antidepressants 0.06 (−0.24, 0.36) 0.18 (−0.13, 0.49)
 Time-varying psychosocial
characteristics
Number of traumatic experiences 0.26 (0.09, 0.43) 0.22 (0.05, 0.40)
Number of stressful life events, past 6
months
0.12 (0.05, 0.20) 0.12 (0.04, 0.19)
Social support scale, per SD −0.29 (−0.50, −0.08) −0.22 (−0.44, 0.01)
PTSD scale, per SD 0.38 (0.24, 0.52) 0.44 (0.30, 0.58)
Beck depression scale, per SD 0.83 (0.68, 0.97) 0.88 (0.73, 1.02)
HADS anxiety scale, per SD
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Table 3







Predictor Coefficient 95% CI
P




Number of stressful events 1.17 (0.69, 1.65) 0.000 0.14 (0.03, 0.24) 0.013
Davidson PTSD score 1.19 (0.82, 1.56) 0.000 0.27 (0.13, 0.42) 0.000
HADS anxiety score 1.63 (1.34, 1.91) 0.000 0.67 (0.52, 0.82) 0.000
Beck Depression Inventory
score 1.52 (1.22, 1.82) 0.000 0.66 (0.50, 0.82) 0.000
Social support −0.54 (−0.93, −0.15) 0.007 −0.11 (−0.29, 0.06) 0.213
Number of childhood
traumas** 0.34 (0.14, 0.54) 0.001
Number of adulthood
traumas 0.26 (−0.07, 0.58) 0.125
Number of all traumas 0.27 (0.10, 0.44) 0.002
Physiologic measures
Aspartate
aminotranspertase 0.07 (−0.36, 0.50) 0.759 −0.02 (−0.18, 0.15) 0.835
Alanine aminotraspertase −0.05 (−0.48, 0.37) 0.802 −0.06 (−0.23, 0.11) 0.478
Gamma glutamyl
transpeptidase* −0.03 (−0.41, 0.34) 0.866 0.01 (−0.26, 0.28) 0.925
Alkaline phosphatase 0.22 (−0.20, 0.63) 0.311 0.03 (−0.14, 0.20) 0.734
Total bilirubin −0.10 (−0.57, 0.36) 0.661 0.00 (−0.14, 0.14) 0.978
TSH −0.27 (−0.66, 0.11) 0.167 −0.13 (−0.31, 0.04) 0.138
Thyroxine 0.07 (−0.37, 0.51) 0.765 0.05 (−0.09, 0.19) 0.457
HIV RNA viral load* 0.31 (−0.14, 0.75) 0.176 0.10 (−0.04, 0.24) 0.156
CD4 count −0.28 (−0.65, 0.08) 0.128 −0.12 (−0.39, 0.14) 0.370
CD4 percent −0.33 (−0.69, 0.03) 0.073 −0.27 (−0.64, 0.10) 0.153
CD8 −0.36 (−0.75, 0.03) 0.072 −0.11 (−0.33, 0.11) 0.319
T4/T8 ratio* −0.27 (−0.65, 0.11) 0.158 0.02 (−0.24, 0.28) 0.874
CD16 count −0.28 (−0.73, 0.18) 0.238 0.02 (−0.12, 0.17) 0.743
CD16 percent −0.14 (−0.61, 0.33) 0.561 0.04 (−0.10, 0.18) 0.591
CD38 on CD8 0.08 (−0.32, 0.49) 0.685 0.06 (−0.10, 0.23) 0.470
Total testosterone −0.35 (−0.72, 0.01) 0.056 0.20 (−0.09, 0.49) 0.179
Free testosterone −0.56 (−0.94, −0.18) 0.004 0.09 (−0.14, 0.33) 0.442
DHEA −0.44 (−0.82, −0.06) 0.024 0.11 (−0.12, 0.35) 0.341
Hemoglobin −0.21 (−0.57, 0.15) 0.254 −0.16 (−0.37, 0.05) 0.134
Hematocrit −0.14 (−0.51, 0.24) 0.475 −0.14 (−0.34, 0.05) 0.143
Serum erythropoietin* −0.27 (−0.68, 0.15) 0.209 0.10 (−0.11, 0.32) 0.347



















Predictor Coefficient 95% CI
P
value Coefficient 95% CI
P
value
Lactic acid −0.18 (−0.66, 0.31) 0.480 0.08 (−0.07, 0.23) 0.292
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Table 4
Between- and within-person associations of psychosocial and physiologic measures with fatigue-related 




Predictor Coefficient 95% CI
P





events 1.15 (0.62, 1.67) 0.000 0.13 (0.02, 0.24) 0.022
Davidson PTSD score 1.31 (0.92, 1.70) 0.000 0.34 (0.19, 0.49) 0.000
HADS anxiety score 1.67 (1.34, 2.00) 0.000 0.68 (0.53, 0.84) 0.000
Beck Depression
Inventory score 1.68 (1.36, 2.00) 0.000 0.70 (0.53, 0.86) 0.000
Social support −0.65 (−1.07, −0.24) 0.002 −0.09 (−0.27, 0.09) 0.312
Number of childhood
traumas** 0.29 (0.08, 0.51) 0.008
Number of adulthood
traumas 0.34 (−0.01, 0.69) 0.054
Number of all traumas 0.26 (0.08, 0.44) 0.005
Physiologic measures
Aspartate
aminotranspertase −0.06 (−0.51, 0.40) 0.813 −0.03 (−0.20, 0.14) 0.746
Alanine aminotraspertase −0.19 (−0.65, 0.27) 0.412 −0.09 (−0.26, 0.08) 0.294
Gamma glutamyl
transpeptidase* −0.08 (−0.49, 0.32) 0.678 −0.02 (−0.30, 0.26) 0.883
Alkaline phosphatase 0.16 (−0.29, 0.60) 0.492 0.06 (−0.11, 0.24) 0.469
Total bilirubin 0.04 (−0.46, 0.54) 0.869 0.08 (−0.07, 0.22) 0.293
TSH −0.28 (−0.69, 0.14) 0.190 −0.09 (−0.27, 0.09) 0.324
Thyroxine 0.05 (−0.43, 0.52) 0.849 0.03 (−0.11, 0.18) 0.649
HIV RNA viral load* 0.33 (−0.14, 0.80) 0.171 0.02 (−0.13, 0.16) 0.803
CD4 count −0.14 (−0.54, 0.25) 0.477 −0.07 (−0.35, 0.20) 0.603
CD4 percent −0.23 (−0.62, 0.15) 0.239 −0.15 (−0.53, 0.23) 0.431
CD8 −0.36 (−0.77, 0.06) 0.093 −0.10 (−0.32, 0.12) 0.388
T4/T8 ratio* −0.21 (−0.61, 0.19) 0.305 −0.09 (−0.35, 0.18) 0.523
CD16 count −0.08 (−0.57, 0.41) 0.744 0.06 (−0.08, 0.21) 0.393
CD16 percent 0.02 (−0.48, 0.52) 0.928 0.05 (−0.09, 0.20) 0.449
CD38 on CD8 0.04 (−0.39, 0.48) 0.847 −0.04 (−0.21, 0.13) 0.673
Total testosterone −0.30 (−0.69, 0.09) 0.133 0.10 (−0.20, 0.39) 0.523
Free testosterone −0.43 (−0.84, −0.02) 0.042 0.03 (−0.21, 0.27) 0.787
DHEA −0.38 (−0.79, 0.04) 0.074 0.04 (−0.19, 0.28) 0.715
Hemoglobin −0.27 (−0.66, 0.12) 0.172 −0.16 (−0.37, 0.05) 0.145
Hematocrit −0.24 (−0.64, 0.16) 0.239 −0.15 (−0.34, 0.05) 0.153

















Predictor Coefficient 95% CI
P
value Coefficient 95% CI
P
value
Serum erythropoietin* −0.11 (−0.56, 0.33) 0.619 0.24 (0.02, 0.46) 0.033
Lactic acid −0.05 (−0.58, 0.48) 0.854 0.06 (−0.09, 0.21) 0.454
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Table 5




Model 2 Model 3*
Time in study (per month) −0.005 (−0.009, −0.000) −0.005 (−0.009, −0.000) −0.004 (−0.008, 0.000)
Psychosocial characteristics
No. of types of traumatic
experiences 0.068 (−0.002, 0.138) −0.001 (−0.069, 0.068) −0.022 (−0.087, 0.043)
Between-person differences:
 Number of recent stressful
life events 0.431 (0.233, 0.629) 0.313 (0.118, 0.507)
 Social support −0.268 (−0.418, −0.118) −0.220 (−0.362, −0.078)
 PTSD symptoms 0.333 (0.173, 0.494)
 Anxiety symptoms 0.527 (0.384, 0.669)
 Depression symptoms 0.476 (0.309, 0.642)
Within-person changes:
 Number of recent stressful
life events 0.081 (0.026, 0.136) 0.075 (0.020, 0.130)
 Social support −0.016 (−0.100, 0.068) −0.012 (−0.096, 0.071)
 PTSD symptoms 0.101 (0.028, 0.175)
 Anxiety symptoms 0.263 (0.184, 0.343)
 Depression symptoms 0.251 (0.169, 0.333)
Socio-demographic
characteristics
African American race −0.052 (−0.370, 0.266) −0.125 (−0.416, 0.166) −0.163 (−0.435, 0.110)
Years of education −0.011 (−0.074, 0.052) −0.036 (−0.094, 0.022) −0.035 (−0.089, 0.020)
Employed −0.076 (−0.236, 0.084) −0.108 (−0.265, 0.049) −0.105 (−0.259, 0.049)
Income (between-person
differences) −0.146 (−0.232, −0.060) −0.145 (−0.223, −0.066) −0.142 (−0.215, −0.068)
Income (withn-person
changes) −0.035 (−0.072, 0.003) −0.023 (−0.061, 0.015) −0.020 (−0.057, 0.018)
Years since HIV diagnosis −0.024 (−0.049, 0.000) −0.013 (−0.036, 0.010) −0.010 (−0.031, 0.012)
Physiologic characteristics
On antiretroviral therapy 0.148 (−0.012, 0.307) 0.181 (0.023, 0.338) 0.171 (0.016, 0.326)
Between-person differences:
 CD4 −0.076 (−0.235, 0.082) −0.108 (−0.253, 0.037) −0.125 (−0.261, 0.011)
 HIV RNA viral load (log10) 0.071 (−0.124, 0.265) 0.022 (−0.160, 0.204) −0.026 (−0.198, 0.146)
 Total testosterone −0.023 (−0.199, 0.152) −0.046 (−0.207, 0.115) −0.037 (−0.188, 0.113)
 DHEA −0.125 (−0.293, 0.042) −0.059 (−0.213, 0.095) −0.027 (−0.172, 0.118)
Within-person changes:
 CD4 −0.009 (−0.146, 0.128) −0.002 (−0.138, 0.134) −0.003 (−0.138, 0.132)

















Model 2 Model 3*
 HIV RNA viral load (log10) 0.057 (−0.018, 0.133) 0.068 (−0.007, 0.143) 0.064 (−0.010, 0.139)
 Total testosterone 0.045 (−0.080, 0.171) 0.053 (−0.071, 0.177) 0.063 (−0.060, 0.186)
 DHEA 0.081 (−0.036, 0.199) 0.079 (−0.038, 0.195) 0.070 (−0.045, 0.186)
*
Due to collinearity, three separate Model 3’s were fit including one of the following: PTSD, anxiety, or depressive symptoms, along with all other 
covariates shown. Coefficients for all other covariates are from the model including PTSD symptoms and did not vary substantially between the 
three Model 3’s.
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